BMI 27 with high blood pressure: weight-loss drug rules

Quick answer: For a prescription, often yes: Wegovy and Zepbound are approved for people who are overweight with a weight-related condition, which in the trials and in Canada's labels means a BMI of 27 or more with something like high blood pressure. Getting it paid for is harder. Medicare's 2026 bridge needs BMI 30 with uncontrolled blood pressure, the NHS currently starts at BMI 35, and Canada's public plans don't cover it.

In this guide

Who this is for — and when medication isn't the first step
What the licence says
Who pays: insurance, Medicare, the NHS and Canada
Compare your options
What to do next
Common questions
Sources

Who this is for — and when medication isn't the first step

This guide is for adults with a BMI around 27 to 29.9 and high blood pressure who want to know whether newer weight-loss medicines such as Wegovy (semaglutide), Zepbound or Mounjaro (tirzepatide) are an option. A BMI in that range counts as overweight rather than obesity, though NICE uses thresholds about 2.5 points lower for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds.

These medicines aren't for you if you're pregnant or planning pregnancy, have had an eating disorder, or have a personal or family history of medullary thyroid cancer or MEN 2, according to the Zepbound label. And whatever you decide, getting your blood pressure treated and controlled matters more in the short term than the number on the scale.

What the licence says

In the US, the Wegovy and Zepbound labels approve them for adults with obesity, or with overweight plus at least one weight-related condition. The labels themselves don't print a BMI cut-off, but the trials that led to approval defined overweight as a BMI of 27 to under 30. Canada's product monographs for Wegovy and Zepbound spell it out: a BMI of 30 or more, or 27 or more with a condition such as high blood pressure, type 2 diabetes, abnormal cholesterol or sleep apnoea.

So a prescriber can consider these medicines at a BMI of 27 with high blood pressure. Whether they will depends on your overall health, and whether anyone will pay depends on rules that are much stricter than the licence.

What counts as high blood pressure

The labels and NICE don't define it beyond "hypertension". In practice that means a diagnosis from your clinician, usually with treatment. US guidelines from 2025 still put stage 1 high blood pressure at 130/80 or above. Medicare's new programme uses a stricter test, set out below.

Who pays: insurance, Medicare, the NHS and Canada

US private insurance

Meeting the label doesn't mean your plan will pay. Many employer plans exclude weight-loss drugs; others cover them after prior authorisation, which usually means showing your BMI, the weight-related condition and sometimes a record of trying diet changes. If you pay yourself, NovoCare sells Wegovy pens at $349 a month, with a $199 starting price for the first two fills for new patients until the end of 2026, and Lilly sells Zepbound vials from $299 to $449 a month.

Medicare

The Medicare GLP-1 Bridge runs from July 2026 to December 2027 with a $50 co-pay. A BMI of 27 with ordinary high blood pressure doesn't qualify. It covers people with a BMI of 35 or more; a BMI of 30 or more with heart failure with preserved ejection fraction, chronic kidney disease stage 3a or worse, or uncontrolled high blood pressure (above 140/90 despite two blood pressure medicines); or a BMI of 27 or more with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Medicare.gov has the details.

The NHS

No, for weight loss at the moment. Wegovy and Mounjaro are recommended from a BMI of 35 with a weight-related condition, and England's GP rollout currently also requires at least four of five conditions. If you already have heart or circulatory disease, ask your GP whether newer NICE guidance on Wegovy for reducing cardiovascular risk applies. Our guide to Wegovy and Mounjaro in the UK has the full NHS criteria.

Canada

Public drug plans don't cover these medicines for weight management. Canada's Drug Agency recommended covering Wegovy only for people with a BMI of 27 or more and established cardiovascular disease, at a lower price, but national price talks ended without agreement in December 2025, according to Global News. Obesity Canada says fewer than one in five private plans cover them. See medical weight loss in Canada for what is covered.

Compare your options

Route	BMI 27 with high blood pressure alone	What changes the answer
Prescription under the licence	Can be considered	Your other health conditions and medicines
US private insurance	Plan by plan	Whether your plan covers weight-loss drugs at all
Medicare GLP-1 Bridge	No	Prediabetes, a past heart attack or stroke, artery disease, or BMI 30 with uncontrolled blood pressure
NHS (England)	No	BMI 35+ (lower for some ethnic backgrounds) with four conditions
Canadian public plans	No	Nothing at present; private plans vary

What to do next

Get your blood pressure treated and controlled — it's the priority either way.
Ask your clinician whether medication makes sense for you, given your other conditions.
Check funding before you start: your insurer's rules, the Medicare bridge tiers, the NHS phase or your provincial and private plan.
If you pay yourself, compare manufacturer self-pay prices with programme fees, and read what regulators say about compounded copies before choosing a cheaper option.
Plan for the long term: weight often returns when these medicines stop.

Check where you stand

The medical weight-loss check works out your BMI, applies the thresholds clinicians use, flags anything that needs a clinician first, and shows the free or covered route before private options.

Check my eligibility

Common questions

Does a BMI of 27 count as overweight or obese?

Overweight. For most adults a BMI of 25 to 29.9 is classed as overweight and 30 or more as obesity. For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background, NICE uses thresholds about 2.5 points lower, because health risks rise at a lower BMI.

Will my insurance cover Wegovy or Zepbound at BMI 27?

It depends on your plan. Meeting the label doesn't mean a plan will pay; many US employer plans exclude weight-loss drugs or require prior authorisation with proof of a weight-related condition. Medicare's 2026 bridge covers BMI 27 only with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.

Can I get weight-loss injections on the NHS with a BMI of 27?

Not for weight loss at the moment. NHS rules start at a BMI of 35 with weight-related conditions, or about 32.5 for some ethnic backgrounds, and the GP rollout currently also needs four conditions. If you already have heart disease, ask your GP whether NICE's guidance on Wegovy for cardiovascular risk applies to you.

Is high blood pressure enough of a reason on its own?

For a prescription it can be, because high blood pressure is one of the weight-related conditions the medicines are approved for. For funding it usually isn't: Medicare's bridge wants blood pressure that stays above 140/90 despite two medicines, and the NHS rollout needs four conditions. Lifestyle changes and blood pressure treatment remain the first steps.

Sources

General information, not medical advice — see our medical disclaimer. Written to the WhereToStart editorial policy. Next scheduled review: 18 April 2027.

BMI 27 with high blood pressure — do I qualify for weight-loss medication?